Tags

Type your tag names separated by a space and hit enter

SARS-CoV-2 viral budding and entry can be modeled using BSL-2 level virus-like particles.
J Biol Chem. 2021 Jan-Jun; 296:100103.JB

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first discovered in December 2019 in Wuhan, China, and expeditiously spread across the globe causing a global pandemic. Research on SARS-CoV-2, as well as the closely related SARS-CoV-1 and MERS coronaviruses, is restricted to BSL-3 facilities. Such BSL-3 classification makes SARS-CoV-2 research inaccessible to the majority of functioning research laboratories in the United States; this becomes problematic when the collective scientific effort needs to be focused on such in the face of a pandemic. However, a minimal system capable of recapitulating different steps of the viral life cycle without using the virus' genetic material could increase accessibility. In this work, we assessed the four structural proteins from SARS-CoV-2 for their ability to form virus-like particles (VLPs) from human cells to form a competent system for BSL-2 studies of SARS-CoV-2. Herein, we provide methods and resources of producing, purifying, fluorescently and APEX2-labeling of SARS-CoV-2 VLPs for the evaluation of mechanisms of viral budding and entry as well as assessment of drug inhibitors under BSL-2 conditions. These systems should be useful to those looking to circumvent BSL-3 work with SARS-CoV-2 yet study the mechanisms by which SARS-CoV-2 enters and exits human cells.

Authors+Show Affiliations

Department of Medicinal Chemistry & Molecular Pharmacology, Purdue Institute of Inflammation, Immunology, and Infectious Disease, Purdue University, West Lafayette, Indiana, USA.Department of Medicinal Chemistry & Molecular Pharmacology, Purdue Institute of Inflammation, Immunology, and Infectious Disease, Purdue University, West Lafayette, Indiana, USA.Department of Medicinal Chemistry & Molecular Pharmacology, Purdue Institute of Inflammation, Immunology, and Infectious Disease, Purdue University, West Lafayette, Indiana, USA.Department of Medicinal Chemistry & Molecular Pharmacology, Purdue Institute of Inflammation, Immunology, and Infectious Disease, Purdue University, West Lafayette, Indiana, USA.Department of Medicinal Chemistry & Molecular Pharmacology, Purdue Institute of Inflammation, Immunology, and Infectious Disease, Purdue University, West Lafayette, Indiana, USA.Department of Medicinal Chemistry & Molecular Pharmacology, Purdue Institute of Inflammation, Immunology, and Infectious Disease, Purdue University, West Lafayette, Indiana, USA.Department of Medicinal Chemistry & Molecular Pharmacology, Purdue Institute of Inflammation, Immunology, and Infectious Disease, Purdue University, West Lafayette, Indiana, USA. Electronic address: rstaheli@purdue.edu.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

33214224

Citation

Plescia, Caroline B., et al. "SARS-CoV-2 Viral Budding and Entry Can Be Modeled Using BSL-2 Level Virus-like Particles." The Journal of Biological Chemistry, vol. 296, 2021, p. 100103.
Plescia CB, David EA, Patra D, et al. SARS-CoV-2 viral budding and entry can be modeled using BSL-2 level virus-like particles. J Biol Chem. 2021;296:100103.
Plescia, C. B., David, E. A., Patra, D., Sengupta, R., Amiar, S., Su, Y., & Stahelin, R. V. (2021). SARS-CoV-2 viral budding and entry can be modeled using BSL-2 level virus-like particles. The Journal of Biological Chemistry, 296, 100103. https://doi.org/10.1074/jbc.RA120.016148
Plescia CB, et al. SARS-CoV-2 Viral Budding and Entry Can Be Modeled Using BSL-2 Level Virus-like Particles. J Biol Chem. 2021 Jan-Jun;296:100103. PubMed PMID: 33214224.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - SARS-CoV-2 viral budding and entry can be modeled using BSL-2 level virus-like particles. AU - Plescia,Caroline B, AU - David,Emily A, AU - Patra,Dhabaleswar, AU - Sengupta,Ranjan, AU - Amiar,Souad, AU - Su,Yuan, AU - Stahelin,Robert V, Y1 - 2020/11/27/ PY - 2020/09/29/received PY - 2020/11/16/revised PY - 2020/11/19/accepted PY - 2020/11/21/pubmed PY - 2021/7/14/medline PY - 2020/11/20/entrez KW - Golgi KW - SARS-CoV-2 KW - coronavirus KW - electron microscopy (EM) KW - membrane bilayer KW - viral protein KW - virology KW - virus KW - virus assembly KW - virus budding KW - virus entry KW - virus-like particle (VLP) SP - 100103 EP - 100103 JF - The Journal of biological chemistry JO - J Biol Chem VL - 296 N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first discovered in December 2019 in Wuhan, China, and expeditiously spread across the globe causing a global pandemic. Research on SARS-CoV-2, as well as the closely related SARS-CoV-1 and MERS coronaviruses, is restricted to BSL-3 facilities. Such BSL-3 classification makes SARS-CoV-2 research inaccessible to the majority of functioning research laboratories in the United States; this becomes problematic when the collective scientific effort needs to be focused on such in the face of a pandemic. However, a minimal system capable of recapitulating different steps of the viral life cycle without using the virus' genetic material could increase accessibility. In this work, we assessed the four structural proteins from SARS-CoV-2 for their ability to form virus-like particles (VLPs) from human cells to form a competent system for BSL-2 studies of SARS-CoV-2. Herein, we provide methods and resources of producing, purifying, fluorescently and APEX2-labeling of SARS-CoV-2 VLPs for the evaluation of mechanisms of viral budding and entry as well as assessment of drug inhibitors under BSL-2 conditions. These systems should be useful to those looking to circumvent BSL-3 work with SARS-CoV-2 yet study the mechanisms by which SARS-CoV-2 enters and exits human cells. SN - 1083-351X UR - https://www.unboundmedicine.com/medline/citation/33214224/SARS_CoV_2_viral_budding_and_entry_can_be_modeled_using_BSL_2_level_virus_like_particles_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0021-9258(20)00093-9 DB - PRIME DP - Unbound Medicine ER -